Cure8 research brief
If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.
Clinicians treating ulcerative colitis; researchers studying IBD biomarkers or biologic therapy response; adult patients interested in precision medicine for UC.
This study analyzed gene expression in colonic mucosal biopsies from ulcerative colitis patients who did and did not respond to infliximab, plus healthy controls, using a multiplex array with RT-qPCR and immunohistochemistry confirmation.
Researchers found a stromal–immune molecular signature in infliximab non-responders, with upregulation of extracellular matrix and stromal remodeling pathways. Two genes/proteins, SPARC and SPP1, were highlighted as the most prominent markers associated with nonresponse and chronic tissue remodeling.
The authors propose that SPARC and SPP1 could be candidate mucosal biomarkers to help stratify patients before biologic therapy, but they emphasize the need for future prospective studies to validate clinical utility. This brief summarizes the article abstract provided by the journal; Cure8 did not review the full paper beyond the supplied source text.
Structured content depth: abstract — this summary is grounded in the source-provided abstract. These findings are preliminary and require prospective validation before being used in clinical decisions.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Ministry of Health, award Ricerca Corrente 2026; award Ricerca Corrente 2026
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
Patients and clinicians often face primary non-response to anti‑TNF therapy. Identifying reproducible mucosal gene-expression patterns linked to non-response helps explain biological differences between responders and...
